martes, 22 de enero de 2013

Joe (NOVARTIS) solo tiene un puñado de $ ($4 billion) para la compra.

Novartis AG will limit deals to $4 billion this year and won’t sell assets such as its money-losing vaccines unit, Chief Executive Officer Joe Jimenez said. “I don’t think we need a big acquisition in the short term,” Jimenez said in an interview at the JPMorgan Chase & Co. health conference in San Francisco. “You may see us do more bolt-ons,” that would range “between $2 billion and $4 billion, not more than that.” 

The Basel, Switzerland-based drugmaker wants to grow its generics business by adding respiratory and dermatology products as well as injectable cancer therapies, Jimenez said. The Swiss drugmaker may do more transactions similar to last year’s $1.5 billion acquisition of closely held Fougera Pharmaceuticals, which allowed it to gain generic skin medications.(Más)

Ver también:

Joe Jimenez/CEO Novartis: "...more money on R&D an...
Publicar un comentario